Eli Lilly and Company

In ATTAIN-MAINTAIN, participants who transitioned from a maximum tolerated dose (MTD) of Wegovy (semaglutide) to Foundayo maintained all…

“This expansion reflects the strength of a long-standing partnership between Lilly and the state of Indiana – one…

Revenue in Q1 2026 increased 56% to $19.8 billion primarily driven by volume growth, partially offset by lower…

Eli Lilly and Company (NYSE:LLY) is one of the best low volatility stocks to invest in right now.…

In ACHIEVE-4, Foundayo met the primary objective of non-inferiority vs. insulin glargine with a 16% lower risk of…

Kelonia’s lead program, KLN-1010, is a potentially first-in-class lentiviral in vivo CAR-T therapy currently in Phase 1 for…

Eli Lilly and Company LLY announced that a phase III study, ACHIEVE-4, evaluating its newly approved oral GLP-1…

We just covered the Jim Cramer Stock Portfolio: Top 10 Stock Picks. Eli Lilly and Company (NYSE:LLY) ranks…

From improved molecular design to AI-driven automation, waves of AI tools promise to accelerate therapeutic development. Still, skeptics…

A safety alert has been issued after falsified Mounjaro pens were found. A safety alert has been issued…

Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Extremely Profitable Stocks to Invest in Now.…

‘Fake fat jab sellers’ warning from health minister who tells the Mirror dodgy weight loss injections can cause…

Lilly’s Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials